Praxis Precision Medicines, Inc. Stock 12‑Month Price Target Raised to $620.95, Implies 95% UpsideTradingView·4 hours agoPRAX+1595.00%
Praxis Q2 2026 results: $1.4 billion liquidity supports runway into 2028TradingKey·14 hours agoPRAX+1595.00%
Praxis Precision Medicines posts investor deck highlighting late-stage CNS pipeline, upcoming PDUFA datesPUBT·15 hours agoPRAX+1595.00%
Praxis Precision Medicines grants 7,318 RSUs to 29 new employees under 2024 inducement planPUBT·2 days ago, 03:02 PMPRAX+1595.00%
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026Unusual Whales·Jul 30 at 03:07 PMPRAX+1595.00%
Praxis Precision Medicines to report Q2 results, host conference call and webcastPUBT·Jul 30 at 03:01 PMPRAX+1595.00%
RBC Capital Remains a Buy on Praxis Precision Medicines (PRAX)Tip Ranks·Jul 10 at 08:47 PMPRAX+1595.00%
Can Praxis Precision Medicines (PRAX) Merit A Higher Valuation As It Expands Ulixacaltamide Delivery?Simplywall·Jul 10 at 08:23 AMPRAX+1595.00%
Praxis Precision Medicines makes equity investment in Remagine LabsPUBT·Jul 7 at 07:03 AMPRAX+1595.00%
